Momenta Phama (MNTA) Posts Mixed Q1 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to Momenta Phama (MNTA) Posts Mixed Q1 Results
May 1, 2015 7:59 AM EDT
CAMBRIDGE, Mass., May 1, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the first quarter ended March 31, 2015.
For the first quarter of 2015, the company reported a net loss of $(21.9) million, or $(0.40) per share, compared to a net loss of $(27.4) million, or $(0.53) per share for the same period in 2014. At March 31, 2015, the company had cash, cash equivalents, and marketable securities of $198.7 million.
"The recent FDA approval of the ANDA for Glatopa, the first generic version of daily COPAXONE 20 mg, was another proud moment for our Company," said Craig Wheeler,... More
May 1, 2015 7:59 AM EDT
CAMBRIDGE, Mass., May 1, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the first quarter ended March 31, 2015.
For the first quarter of 2015, the company reported a net loss of $(21.9) million, or $(0.40) per share, compared to a net loss of $(27.4) million, or $(0.53) per share for the same period in 2014. At March 31, 2015, the company had cash, cash equivalents, and marketable securities of $198.7 million.
"The recent FDA approval of the ANDA for Glatopa, the first generic version of daily COPAXONE 20 mg, was another proud moment for our Company," said Craig Wheeler,... More
